Novartis joins seven global companies to found the Value Balancing Alliance

A new AI-enabled disease management tool in China aims to improve the lives of millions of patients with heart failure.

Novartis data at 2019 ASH and SABCS underscore our evolving R&D approach in innovative platforms to reimagine medicine and help improve patient outcomes.

This year, World Malaria Day is running with the backdrop of countries around the world continuing to fight the COVID-19 pandemic.

The Corporate Reputation of Pharma 2019 global report reflects the findings of a survey conducted by PatientView with patient organizations worldwide.

The event, called “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016, on the Novartis Campus in Basel, Switzerland and will also be webcast.

The event will take place on November 21 in Basel.

European Patient Innovation Summit publishes a position paper on Digital Health from a Patient Perspective with recommendations on digital health.

On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.

From January 13-16 2020, Novartis attended the J.P Morgan Healthcare Conference in San Francisco.